Navigation Links
A cancer-promoting protein is found to also suppress cell growth
Date:3/7/2013

of mRNA into the amino-acid chains that make proteins.

More recently, Dr. Fregoso, together with graduate student Shipra Das in Krainer's lab found that SRSF1 interacts with RPL5 as part of a complex that is not involved in their respective roles in splicing or the ribosome. They showed that this complex prevents the degradation of the powerful tumor-suppressor protein p53.

Yet Krainer's team also showed that increased expression of SRSF1 in primary human fibroblast cells decreased their proliferation and triggered a cellular senescence program in which cell growth is arrested. "It's a little surprising because we've published about SRSF1 being oncogenic, and here we find it stabilizing a tumor-suppressor protein," Krainer acknowledged. "But this seems to be a theme with oncogenes: the cells try to respond to their activity by undergoing senescence," a quiescent state in which cells don't replicate.

The process of cell-cycle arrest in response to oncogenic stress is known as oncogene induced senescence (OIS) and was described at CSHL by Scott Lowe's laboratory in 1997 [link: http://www.sciencedirect.com/science/article/pii/S0092867400819029]. That discovery was the first indication that normal cells have a mechanism in place that acts to prevent transformation into a cancer cell.

Through the interaction of the splicing protein SRSF1 and the ribosomal protein RLP5 Krainer's new research also identifies a link between oncogenic stress and the ribosomal stress response. This was found to result in the activation of p53 and cell-growth arrest. "We've identified a novel mechanism by which the oncoprotein SRSF1 keeps a check on its own aberrant activity," noted Das. "The discovery of this novel role for SRSF1 enhances our understanding of how tumors arise and the pathways to transformation," added Krainer.


'/>"/>

Contact: Edward Brydon Ph.D.
ebrydon@cshl.edu
516-367-6822
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1 2

Related biology news :

1. Age-related dementia may begin with neurons inability to dispose of unwanted proteins
2. Stressed proteins can cause blood clots for hours
3. Adding to the list of disease-causing proteins in brain disorders
4. Analytical trick accelerates protein studies
5. Antibacterial proteins molecular workings revealed
6. Nano-machines for bionic proteins
7. Bridges experimental and bioinformatics perspectives to delineate protein-DNA interactions
8. Discovering cell surface proteins behavior
9. Newly identified natural protein blocks HIV, other deadly viruses
10. Protein filmed while unfolding at atomic resolution
11. Key protein revealed as trigger for stem cell development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... 8, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... members of the executive management team will present at the ... Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company Technology, ... ET Location: The New York Palace Hotel, New ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... (ACT) therapy is used to treat patients with metastatic solid ... cancer cells, and some of their immune T cells. When ... cells that stimulate the T cells to cause an immune ... re-infused into the patient to mount an immunological, anti-cancer response ...
... died in Britain of cancer of the liver. Eventually, researchers ... aflatoxin as the cause of this mysterious 'turkey X' disease. ... most virulent natural carcinogenic substances. , The tasteless toxin is ... arid regions, in the south-west of the US and in ...
... Rutgers University will lead a new $52.7 million research ... play in life's most fundamental processes and point the ... Rutgers Professor Gaetano Montelione, the Northeast Structural Genomics Consortium ... one of the largest in Rutgers' history, will reinforce ...
Cached Biology News:Corn grain mould used as pesticide 2Rutgers to lead $52.7 million protein research program 2Rutgers to lead $52.7 million protein research program 3Rutgers to lead $52.7 million protein research program 4
(Date:6/3/2015)... UK, and BRUSSELS, Belgium (PRWEB) June 03, 2015 ... and beyond, photonics plays an important part in enabling ... the European Commission. Innovation and technology leaders helped bring ... in thematic sessions during the Photonics21 annual meeting ... was a sponsor of the event, held 28 and ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) has ... by Product , Test, Application & End User - ... The bioburden testing market is expected to reach ... growing at a CAGR of 9.8% from 2014 to ... limit testing market is segmented into consumables and instruments. ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ) has announced the addition ... by Products - Global Forecast to 2020" report ... is expected to reach $17.0 Billion in 2020 from ... during the forecast period of 2015 to 2020 ... of a range of products for wide applications, decreasing ...
(Date:6/2/2015)... Pa. , June 2, 2015   BioClinica ... and technology provider, today announced that David Peters ... been named Executive Vice President and Chief Financial Officer ... 2015. Peters brings more than 25 years ... pharmaceutical services. "David has extensive and deep knowledge in ...
Breaking Biology Technology:Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2BioClinica Names David Peters New Chief Financial Officer 2
... NEW YORK, April 10 Intellect Neurosciences,Inc. (OTC ... obtained a,Notice of Allowance and completed the grant ... Company,s ANTISENILIN(R) antibodies and,products being developed by the ... the European patent is expected in several weeks. ...
... Va., April 10 Insmed Inc. (Nasdaq:,INSM), a ... of a letter and questionnaire from the Chairman ... Subcommittee on Health,on the possible development of legislation ... Sent to approximately 30 stakeholders in the biotechnology ...
... Product Candidate -, PRINCETON, N.J., April 10, ... and protein production,company, today announced that it has ... Pharmaceuticals, LLC. According to the,agreement, Laureate will produce ... is planned for use in clinical trials, and ...
Cached Biology Technology:Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 2Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 3Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 4Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 2Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 3Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 2Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 3
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
Biology Products: